| Title |
SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials
|
|---|---|
| Published in |
Diabetologia, July 2017
|
| DOI | 10.1007/s00125-017-4370-8 |
| Pubmed ID | |
| Authors |
Huilin Tang, Qi Dai, Weilong Shi, Suodi Zhai, Yiqing Song, Jiali Han |
| Abstract |
The association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and the risk of cancer in individuals with type 2 diabetes remains uncertain. This study aimed to evaluate the risk of cancer associated with SGLT2 inhibitor treatment of type 2 diabetes. We systematically searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov from inception to 15 February 2017 to identify eligible randomised controlled trials (RCTs) that report cancer events in individuals with type 2 diabetes treated with SGLT2 inhibitors for at least 24 weeks. We performed pairwise and network meta-analyses as well as a cumulative meta-analysis to calculate ORs and 95% CIs. In total, 580 incidences of cancer among 34,569 individuals were identified from 46 independent RCTs with a mean trial duration of 61 weeks. When compared with comparators (placebo or other active glucose-lowering treatments), SGLT2 inhibitors were not significantly associated with an increased risk of overall cancer (OR 1.14 [95% CI 0.96, 1.36]). For pre-specified cancer types, the risk of bladder cancer might be increased with SGLT2 inhibitors (OR 3.87 [95% CI 1.48, 10.08]), especially empagliflozin (OR 4.49 [95% CI 1.21, 16.73]). Interestingly, canagliflozin might be protective against gastrointestinal cancers (OR 0.15 [95% CI 0.04, 0.60]). Current evidence from short-term RCTs did not indicate a significantly increased risk of overall cancer among individuals with type 2 diabetes using SGLT2 inhibitors. Given the short-term trial durations and uncertainty of evidence, future long-term prospective studies and post-marketing surveillance studies are warranted. |
X Demographics
The data shown below were collected from the profiles of 75 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 11 | 15% |
| Japan | 7 | 9% |
| Canada | 4 | 5% |
| India | 3 | 4% |
| United States | 3 | 4% |
| France | 2 | 3% |
| United Kingdom | 2 | 3% |
| Mexico | 1 | 1% |
| Ireland | 1 | 1% |
| Other | 2 | 3% |
| Unknown | 39 | 52% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 59 | 79% |
| Scientists | 8 | 11% |
| Practitioners (doctors, other healthcare professionals) | 7 | 9% |
| Science communicators (journalists, bloggers, editors) | 1 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 135 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 135 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 12% |
| Student > Master | 15 | 11% |
| Student > Bachelor | 15 | 11% |
| Student > Ph. D. Student | 12 | 9% |
| Student > Postgraduate | 11 | 8% |
| Other | 29 | 21% |
| Unknown | 37 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 47 | 35% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 13% |
| Biochemistry, Genetics and Molecular Biology | 9 | 7% |
| Nursing and Health Professions | 5 | 4% |
| Agricultural and Biological Sciences | 3 | 2% |
| Other | 15 | 11% |
| Unknown | 39 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 90. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2023.
All research outputs
#478,260
of 25,726,194 outputs
Outputs from Diabetologia
#247
of 5,376 outputs
Outputs of similar age
#9,907
of 326,015 outputs
Outputs of similar age from Diabetologia
#10
of 87 outputs
Altmetric has tracked 25,726,194 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,376 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.8. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,015 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 87 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.